Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated November 18, 2025, serves as a transaction notification for the month of November 2025. The document discloses specific share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them, executed on the New York Stock Exchange.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on individual insider transactions involving American Depositary Shares (ADSs).
| Transaction Date | Instrument | Price per ADS | Total Volume |
|---|---|---|---|
| 2025-11-14 | ADSs (ISIN: US37733W2044) | $47.1800 | 2,852.688 (Aggregated) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine dividend reinvestment transactions rather than strategic shifts or financial variances compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions reported are automatic acquisitions within executive savings plans following dividend reinvestments.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ADSs via dividend reinvestment plans, not open-market purchases or sales.
- Insiders Involved:
- Dr. Hal Barron (Non-Executive Director): Acquired 2,801.837 ADSs (2,732.837 via Executive Supplemental Savings Plan; 69 via 401(k) plan).
- James Ford (SVP and Group General Counsel): Acquired 50.851 ADSs via Executive Supplemental Savings Plan.
- Market Price: The transactions occurred at a uniform price of $47.18 per ADS on November 14, 2025.
- Scope Limitation: This filing does not provide any data on GSK's overall financial performance for the period.